Matrix metalloproteinase-1 is regulated in tuberculosis by a p38 MAPK-dependent, p-aminosalicylic acid-sensitive signaling cascade

Journal of Immunology

Volumn 182, Issue 9, 2009, Pages 5865-5872

  Rand, Lucinda ^a   Green, Justin A ^a   Saraiva, Luísa ^a   Friedland, Jon S ^a   Elkington, Paul T G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CYCLOOXYGENASE 2; INTERSTITIAL COLLAGENASE; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN E2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; MMP1 PROTEIN, HUMAN; MMP7 PROTEIN, HUMAN; TUBERCULOSTATIC AGENT;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME RELEASE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG GRANULOMA; LUNG TUBERCULOSIS; MACROPHAGE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PHOSPHORYLATION; PHYSIOLOGY; SECRETION;

ANTITUBERCULAR AGENTS; CELLS, CULTURED; DINOPROSTONE; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 7; MYCOBACTERIUM TUBERCULOSIS; P-AMINOSALICYLIC ACID; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUBERCULOSIS, PULMONARY;

EID: 66949171433     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0801935     Document Type: Article

References (44)

1. Raviglione, M. C., and I. M. Smith. 2007. XDR tuberculosis: implications for global public health. N. Engl. J. Med. 356: 656-659. (Pubitemid 46257227)
2. Kaplan, G., F. A. Post, A. L. Moreira, H. Wainwright, B. N. Kreiswirth, M. Tanverdi, B. Mathema, S. V. Ramaswamy, G. Walther, L. M. Steyn, et al. 2003. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 71: 7099-7108. (Pubitemid 37475342)
3. Rosenberger, C., and B. Finlay. 2003. Phagocyte sabotage: disruption of macrophage signalling by bacterial pathogens. Nat. Rev. Mol. Cell Biol. 4: 385-396. (Pubitemid 36565570)
4. Chang, J. C., A. Wysocki, K. M. Tchou-Wong, N. Moskowitz, Y. Zhang, and W. N. Rom. 1996. Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 51: 306-311.
5. Price, N. M., R. H. Gilman, J. Uddin, S. Recavarren, and J. S. Friedland. 2003. Unopposed matrix metalloproteinase-9 expression in human tuberculous granuloma and the role of TNF-α-dependent monocyte networks. J. Immunol. 171: 5579-5586.
6. Quiding-Jarbrink, M., D. A. Smith, and G. J. Bancroft. 2001. Production of matrix metalloproteinases in response to mycobacterial infection. Infect. Immun. 69: 5661-5670. (Pubitemid 32786504)
7. Rivera-Marrero, C. A., W. Schuyler, S. Roser, J. D. Ritzenthaler, S. A. Newburn, and J. Roman. M. 2002. Tuberculosis induction of matrix metalloproteinase-9: the role of mannose and receptor-mediated mechanisms. Am. J. Physiol. 282: L546-L555.
8. Elkington, P. T., R. K. Nuttall, J. J. Boyle, C. M. O'Kane, D. E. Horncastle, D. R. Edwards, and J. S. Friedland. 2005. Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am. J. Respir. Crit. Care Med. 172: 1596-1604.
9. Page-McCaw, A., A. J. Ewald, and Z. Werb. 2007. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8: 221-233. (Pubitemid 46310551)
10. Greenlee, K. J., Z. Werb, and F. Kheradmand. 2007. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol. Rev. 87: 69-98. (Pubitemid 46209991)
11. Crystal, R. G., and J. B. West. 1997. The Lung: Scientific Foundations. Lippincott, Philadelphia, 1997.
12. Filippov, S., I. Caras, R. Murray, L. M. Matrisian, H. A. Chapman, Jr., S. Shapiro, and S. J. Weiss. 2003. Matrilysin-dependent elastolysis by human macrophages. J. Exp. Med. 198: 925-935.
13. Segura-Valdez, L., A. Pardo, M. Gaxiola, B. D. Uhal, C. Becerril, and M. Selman. 2000. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 117: 684-694. (Pubitemid 30152206)
14. Imai, K., S. S. Dalal, E. S. Chen, R. Downey, L. L. Schulman, M. Ginsburg, and J. D'Armiento. 2001. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am. J. Respir. Crit. Care Med. 163: 786-791. (Pubitemid 32230844)
15. Elkington, P. T., and J. S. Friedland. 2006. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 61: 259-266.
16. Parks, W. C., C. L. Wilson, and Y. S. Lopez-Boado. 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4: 617-629. (Pubitemid 39025047)
17. Brew, K., D. Dinakarpandian, and H. Nagase. 2000. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477: 267-283. (Pubitemid 30119906)
18. Elkington, P. T., J. E. Emerson, L. D. Lopez-Pascua, C. M. O'Kane, D. E. Horncastle, J. J. Boyle, and J. S. Friedland. 2005. Mycobacterium tuberculosis up-regulates matrix metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch. J. Immunol. 175: 5333-5340.
19. Pillinger, M. H., P. B. Rosenthal, S. N. Tolani, B. Apsel, V. Dinsell, J. Greenberg, E. S. Chan, P. F. Gomez, and S. B. Abramson. 2003. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J. Immunol. 171: 6080-6089.
20. Lai, W. C., M. Zhou, U. Shankavaram, G. Peng, and L. M. Wahl. 2003. Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J. Immunol. 170: 6244-6249.
21. Reunanen, N., J. Westermarck, L. Hakkinen, T. H. Holmstrom, I. Elo, J. E. Eriksson, and V. M. Kahari. 1998. Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J. Biol. Chem. 273: 5137-5145. (Pubitemid 28108675)
22. Mercer, B. A., N. Kolesnikova, J. Sonett, and J. D'Armiento. 2004. Extracellular regulated kinase/Mitogen activated protein kinase is up-regulated in pulmonary emphysema and mediates matrix metalloproteinase-1 induction by cigarette smoke. J. Biol. Chem. 279: 17690-17696.
23. Wahl, L. M., M. E. Corcoran, S. E. Mergenhagen, and D. S. Finbloom. 1990. Inhibition of phospholipase activity in human monocytes by IFN-γ blocks endogenous prostaglandin E2-dependent collagenase production. J. Immunol. 144: 3518-3522.
24. Graessle, O. E., and J. J. Pietrowski. 1949. The in vitro effect of para-aminosalicylic acid (PAS) in preventing acquired resistance to streptomycin by Mycobacterium tuberculosis. J. Bacteriol. 57: 459-464.
25. Rengarajan, J., C. M. Sassetti, V. Naroditskaya, A. Sloutsky, B. R. Bloom, and E. J. Rubin. 2004. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol. Microbiol. 53: 275-282. (Pubitemid 38901397)
26. Iseman, M. D. 2002. Tuberculosis therapy: past, present and future. Eur. Respir. J. Suppl. 36: 87s-94s.
27. Elkington, P. T., J. A. Green, and J. S. Friedland. 2006. Filter sterilization of highly infectious samples to prevent false negative analysis of matrix metalloproteinase activity. J. Immunol. Methods 309: 115-119.
28. Nuttall, R. K., C. J. Pennington, J. Taplin, A. Wheal, V. W. Yong, P. A. Forsyth, and D. R. Edwards. 2003. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol. Cancer. Res. 1: 333-345.
29. Jo, E. K., C. S. Yang, C. H. Choi, and C. V. Harding. 2007. Intracellular signalling cascades regulating innate immune responses to Mycobacteria: branching out from Toll-like receptors. Cell. Microbiol. 9: 1087-1098.
30. Pathak, S. K., S. Basu, K. K. Basu, A. Banerjee, S. Pathak, A. Bhattacharyya, T. Kaisho, M. Kundu, and J. Basu. 2007. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. Nat. Immunol. 8: 610-618.
31. Davies, S. P., H. Reddy, M. Caivano, and P. Cohen. 2000. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351: 95-105.
32. Dean, J. L., M. Brook, A. R. Clark, and J. Saklatvala. 1999. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J. Biol. Chem. 274: 264-269.
33. Song, C. H., J. S. Lee, S. H. Lee, K. Lim, H. J. Kim, J. K. Park, T. H. Paik, and E. K. Jo. 2003. Role of mitogen-activated protein kinase pathways in the production of tumor necrosis factor-α, interleukin-10, and monocyte chemotactic protein-1 by Mycobacterium tuberculosis H37Rv-infected human monocytes. J. Clin. Immunol. 23: 194-201.
34. Jung, S. B., C. H. Song, C. S. Yang, S. Y. Kim, K. S. Lee, A. R. Shin, J. S. Lee, H. S. Nam, H. J. Kim, J. K. Park, et al. 2005. Role of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in the secretion of tumor necrosis factor-α and interleukin-10 by the PPD antigen of Mycobacterium tuberculosis. J. Clin. Immunol. 25: 482-490.
35. phox activation is essential for inflammatory responses during tuberculosis via TLR2-ROS signalling. Cell. Microbiol. 10: 741-754.
36. Malemud, C. J. 2007. Inhibitors of stress-activated protein/mitogen- activated protein kinase pathways. Curr. Opin. Pharmacol. 7: 339-343. (Pubitemid 46731194)
37. Harris, S. G., J. Padilla, L. Koumas, D. Ray, and R. P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends. Immunol. 23: 144-150.
38. Shapiro, S. D., D. K. Kobayashi, A. P. Pentland, and H. G. Welgus. 1993. Induction of macrophage metalloproteinases by extracellular matrix: evidence for enzyme- and substrate-specific responses involving prostaglandin-dependent mechanisms. J. Biol. Chem. 268: 8170-8175.
39. Basu, S., S. Pathak, S. K. Pathak, A. Bhattacharyya, A. Banerjee, M. Kundu, and J. Basu. 2007. Mycobacterium avium-induced matrix metalloproteinase-9 expression occurs in a cyclooxygenase-2-dependent manner and involves phosphorylation- and acetylation-dependent chromatin modification. Cell. Microbiol. 9: 2804-2816. (Pubitemid 350066566)
40. Hernandez-Pando, R., H. Orozco-Esteves, H. A. Maldonado, D. Aguilar-Leon, M. M. Vilchis-Landeros, D. A. Mata-Espinosa, V. Mendoza, and F. Lopez-Casillas. 2006. A combination of a transforming growth factor-β antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis. Clin. Exp. Immunol. 144: 264-272.
41. Byrne, S. T., S. M. Denkin, and Y. Zhang. 2007. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J. Antimicrob. Chemother. 59: 313-316.
42. Lehman, J. 1946. para-Aminosalicylic acid in the treatment of tuberculosis. Lancet I: 15-16.
43. Saklatvala, J. 2004. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr. Opin. Pharmacol. 4: 372-377. (Pubitemid 38987064)
44. Wallis, R. S. 2005. Reconsidering adjuvant immunotherapy for tuberculosis. Clin. Infect. Dis. 41: 201-208.